Loading stock data…
Eledon Pharmaceuticals, Inc. (ELDN)
$3.88+0.10 (+2.65%)
After Hours$3.99+0.11 (+2.79%)· Last close Jun 29
Eledon Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eledon Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.88 with a market capitalization of $269M. Wall Street consensus targets $9.00 (5 analysts), implying a +132.0% move over the next 12 months. The stock is currently 16% below its 52-week high of $4.60, remaining 40.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +132.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.18M↑ | -$21.48M↓ | -$19.07M↑ | -$24.73M↓ | -$17.96M |
| Net Income | -$39.02M↓ | -$10.45M↑ | -$17.46M↓ | -$11.22M↓ | -$6.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$269.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-174.58%
Volume
Today's trading volume
2.20M
Recent News
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart
While Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has gained 125.83% year-to-date, analysts continue to see 134.60% upside, helping it secure a spot on our list of the hot biotech stocks under $5 to buy. Updated clinical data presented at a major diabetes conference added weight to the case that Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)’s lead drug could reshape […]
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc., as its primary long-term value driver. Twito added that the company's stem cell-derived islet platform, combined with targeted immune prote
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company […]